Rationale: Early detection of chronic obstructive pulmonary disease (COPD) exacerbations using telemonitoring of physiological variables might reduce the frequency of hospitalization.
Chronic obstructive pulmonary disease (COPD) is common, impairs quality of life, and is a leading cause of death worldwide (1) . Comorbid conditions, such as cardiovascular disease, often coexist with COPD, leading to worse outcomes (2) . Both comorbidity and increasing age are associated with less-effective COPD self-management (3), more frequent hospitalization (4) , and higher mortality (5) (6) (7) .
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines use frequency of exacerbation and hospitalization to stratify risk and direct treatment for patients with COPD and consider exacerbation reduction as a core management goal (1) . Pharmacological therapy (1) , pulmonary rehabilitation (8) , and influenza vaccination (9) all reduce the exacerbation rate, but their impact is modest. The use of remote telemonitoring to detect exacerbations early is attractive, as it might reduce exacerbation duration, severity, and the need for hospitalization, a major driver of healthcare costs (10) . To date, most telemonitoring studies in COPD have monitored symptoms and simple physiological measures, such as heart rate and oxygen saturation, alongside enhanced clinical support (11) (12) (13) (14) (15) , and only a few included physiological measurements such as peak expiratory flow rate (16) . The outcomes of these studies have been disappointing, with limited evidence of health or economic benefit (12, 17) . Moreover, none included objective, effort-independent measurements of pulmonary function.
The forced oscillation technique (FOT) measures the mechanical properties of the lung during tidal breathing in a way that is simple to perform without supervision or effort, is operator independent, and can be undertaken at home by patients with COPD (18, 19) . FOT can also detect changes in lung mechanics acutely after a bronchodilator (20) and during recovery from an exacerbation (21) (22) (23) , making it a potentially attractive way to objectively define exacerbation events in a telemonitoring program.
We hypothesized that, in older patients with both COPD and comorbidities, remote respiratory monitoring using daily FOT measurements, with or without enhanced cardiac monitoring, would reduce the time to first hospitalization (TTFH), increase quality of life, and reduce healthcare costs. To test this hypothesis, we conducted the CHROMED (Clinical Trials for Elderly Patients with Multiple Disease) study, an international randomized controlled trial funded by the European Commission (project ID: 306093).
Methods
CHROMED was a multicenter, randomized, unblinded, parallel-group clinical trial. Patients were recruited at six sites in five countries: Spain, United Kingdom, Slovenia, Estonia, and Sweden (see online supplement for details). The study was registered on ClinicalTrials.gov: NCT01960907.
Patients
We recruited patients aged 60 years or older, with a diagnosis of COPD GOLD grade II or higher (24) , a history of acute exacerbation with or without hospitalization in the previous 12 months, a smoking history of greater than or equal to 10 pack-years, and one or more documented nonpulmonary chronic conditions (see online supplement). These included congestive heart failure (CHF), ischemic heart disease (IHD), hypertension, hyperlipidemia, and clinically significant sleep-disordered breathing. Patients with significant visual disturbance or mental health disorders that would make them unable to use the monitoring platform, a planned prolonged absence from home, living in areas not covered by a mobile data network, or unable to use the study equipment were excluded. Patients were clinically stable, with at least 4 weeks elapsed since their last exacerbation.
All patients provided written informed consent, and the protocol was approved by the ethical review boards of participating institutions.
Protocol
At recruitment, we recorded demographic data, measured spirometry before and 15 minutes after inhaling 200 mg salbutamol, and administered the St. George's Respiratory Questionnaire, the COPD Assessment Tool (CAT) (25) , the EuroQoL EQ-5D questionnaire (26) , and the Patient Health Questionnaire (PHQ-9) (27). Patients with CHF or IHD also completed the Minnesota Living with Heart Failure questionnaire (MLHFQ) (28) .
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At a Glance Commentary
Scientific Knowledge on the Subject: Despite observational studies suggesting that chronic obstructive pulmonary disease exacerbation can be detected using a combination of symptoms and physiological measures, such as pulse and oxygen saturation, larger randomized controlled trials have not shown any effect of telemonitoring on time to first hospital admission, hospitalization, and quality of life. Tested telemonitoring programs had a negligible impact on healthcare costs, and, in some cases, resulted in increased healthcare use.
What This Study Adds to the
Field: This randomized controlled trial of 312 patients with chronic obstructive pulmonary disease is the first using only objective lung function data measured daily by the forced oscillation technique to prompt early intervention. Despite being feasible and well accepted by patients, this approach did not affect time to first hospital admission and quality of life. However, it significantly reduced healthcare costs, mostly because of a reduction in duration and frequency of subsequent hospitalizations, which was greatest in patients hospitalized the year before recruitment.
to intervention or control groups (1:1) using a concealed computer-generated randomization sequence with a fourelement block design and stratified on a clinical center basis. The intervention group used the CHROMED monitoring platform for 9 months at approximately the same time each day. The platform comprised a device that measured within-breath respiratory mechanical impedance (RESMON PRO DIARY; Restech s.r.l.) using FOT, a touch-screen computer, and a mobile modem. Patients with a diagnosis of CHF used an additional wearable device to assess blood pressure, oxygen saturation, heart rate, and body temperature (WristClinic; Medic4All) over a 4-minute period. FOT measurements were cleaned automatically from artifacts using previously published filtering rules (29) and automatically sent to the study server. An algorithm generated respiratory alerts if a trend of worsening was detected in at least one of the following FOT parameters measured at 5 Hz: inspiratory resistance, inspiratory reactance, or the difference between inspiratory and expiratory reactance, an index of the presence of tidal expiratory flow limitation (30, 31) . Specifically, a worsening was deemed to occur when a statistically significant (P , 0.05) linear increase of inspiratory resistance, difference between inspiratory and expiratory reactance, or decrease of inspiratory reactance with a correlation coefficient of at least 0.4 was detected in a time window of 10 days, including the current measurement (see online supplement). Additional cardiac alerts were generated if blood pressure and/or heart rate and/or blood oxygen saturation and/or body temperature exceeded specific limits established in the baseline period on at least 2 consecutive days (see Table E2 in the online supplement). Cardiac thresholds were adapted for each patient depending on baseline measurements. Missing FOT data were interpolated if at least four nonconsecutive FOT measurements in the past 10 days were present. Cardiac measurements were analyzed if at least two consecutive days of data were present. The alert triggered a contact with the study nurse to determine the patient's clinical status and whether any intervention was required. After contact, a variety of actions were possible, ranging from no action to taking a course of antibiotics and/or corticosteroids or face-to-face assessment. We did not recommend specific criteria for hospitalization, this decision being made on clinical grounds by the reviewing physician. Technical alerts were issued if no data were recorded for more than 2 days. When this occurred, the local site contacted the study patient. Patients in the control group received usual care according to their local practice.
Every 3 months, all participants were telephoned to establish their use of antibiotic/corticosteroids (moderate COPD exacerbations) and primary care resources and to complete the EQ-5D questionnaire. Every 2 months, participants were telephoned and completed the CAT, PHQ-9, and MLHFQ questionnaires. Hospital admissions were identified from clinical records at the end of the trial. A detailed description of the study protocol is provided in the online supplement.
Study Outcomes
The predefined coprimary endpoints were TTFH and change in the EQ-5D utility index score. Secondary outcomes included moderate exacerbation rate, hospitalization, and final scores of the CAT, PHQ-9, and MLHFQ questionnaires. A cost-utility analysis was also performed to measure whether the intervention was cost effective by comparing healthcare costs and quality-adjusted life years (QALYs) in the two groups. Costs were analyzed with a healthcare system perspective and included hospital and primary care resources, remote follow-ups, and management of medical alarms. Because the platform was still a prototype, the costs of the equipment and technical support could not be included (see online supplement). We defined rehospitalization as any hospital admission that occurred during the study period after the first hospitalization.
Sample Size
Two main outcomes were chosen for this study. Assuming that 60% of the study population would not be hospitalized at 9 months (32), a study population of 310 patients was calculated to detect a 25% increase in the TTFH with a type I error risk of 0.05 and a power of 80%. Moreover, using 0.73 6 0.22 (mean 6 SD) as an estimate of the expected EQ-5D utility score in the study population (26) and anticipating a 10% dropout rate and 5% mortality rate, a sample size of at least 148 patients was needed to evaluate a minimum detectable difference of 15% of the EQ-5D utility score, with the same level of type I error and power used for TTFH.
Statistical Analysis
Data are expressed as median and interquartile range (IQR) unless otherwise stated and were analyzed by intention to treat. TTFH used the Kaplan-Meier survival plot. Between-group significance was tested with the log-rank test. Rates of prescription of antibiotics/corticosteroids (moderate exacerbations), hospital admissions, and readmission for COPD were calculated assuming a negative binomial distribution, with number of events as the outcome, study group as single covariate, and the logarithm of time of observation as offset variable (33) . Between-group comparisons are expressed as incidence rate ratios. We considered a P value , 0.05 to be significant for the primary outcomes and all other P values to be exploratory if the primary outcomes were negative.
An exploratory subgroup analysis was performed in patients with a potentially higher risk of hospitalization defined by: 1) a diagnosis of CHF and/or IHD, 2) COPD GOLD grade III and IV (24), 3) at least two exacerbations in the year preceding the study, and 4) at least one hospital admission due to a COPD exacerbation in the year before the study.
All statistical analyses were performed by using IBM SPSS Statistics. A full description of the methodology used is reported in the online supplement.
Results
Patients were recruited from Oct 15, 2013 to July 3, 2015. Of 326 patients screened, 14 declined to participate because of concerns about the equipment or inability to perform the measurements. A total of 312 patients (75 from the United Kingdom, 80 from Estonia, 63 from Sweden, 61 from Spain, and 33 from Slovenia) were randomized (154 intervention, 158 control). Of those, 109 (71%) in the intervention and 122 (77%) in the control group were successfully monitored for 9 months (Figure 1) . Overall, 88% (IQR, 77-95%) of the expected daily FOT measurements and 93% (IQR, 63-98%) of the additional cardiac measurements for patients with cardiac comorbidities were completed.
Baseline Demographics
The groups were well matched for anthropometrics, disease severity, prior exacerbations, hospitalizations, comorbidity, and the season they entered the study (Table 1) . Enrolled patients had a median age of 71 years, 97% had one or more comorbidity (predominantly cardiovascular), and 49.7% had moderate, 37.2% severe, and 13.1% very severe COPD (24) . All patients had exacerbated in the past year, and 60.9% exacerbated twice or more. Only 41.3% were hospitalized with a COPD exacerbation in the previous year.
Medical Alerts
All the patients in the intervention group performed daily FOT measurements, and 37 (24%) performed additional daily cardiac assessments. On average, 0.5 (IQR, 0.3-0.9) alerts/patient/mo were generated based on FOT parameters and 1.1 (IQR, 0.8-1.4) alerts/patient/mo by change in the cardiac parameters. Alerts were followed by a call from the study nurse within 1.4 6 3.7 days of their generation. In 4,039 days out of 36,600 days of FOT monitoring (11%) and 1,164 days out of 8,406 days of cardiac monitoring (14%) the system could not generate any alerts due to missing measurements. Missing data were primarily due to patient forgetfulness or being in vacation/out of the town (45%), bad coverage of the mobile network preventing a stable data transmission (35%), technical failure of the monitoring equipment (18%), and hospitalization of the patient (3%). In half of the respiratory alerts, patients reported one or more symptom changes, including increased breathlessness (66%), increased cough (42%), loss of energy (35%), and increased wheeze or chest tightness (28%). A similar proportion of cardiac alerts were symptomatic, with breathlessness (15%) and loss of energy (18%) the most frequent problems. Respiratory and cardiac alerts led to a change of treatment or face-toface visit in 34% and 37% of cases, respectively. Further detail is provided in the online supplement (Table E1) .
Healthcare Use-defined Exacerbations
In total, 38 (48%) hospital admissions in the intervention group had an alert in the preceding 2 weeks, and 21 (27%) were treated by the nurses/clinicians managing the alarm. Mean TTFH was 224 days (IQR, 209-240 d) in the intervention group and 254 days (IQR, 240-270 d) in the control group (P = 0.342) (Figure 2 ). There was no difference between groups in the rate of moderate exacerbations (1.74 vs. 1.52, P = 0.499), hospitalization (0.79 vs. 0.99, P = 0.276), or the number of patients free from hospital admission (71% vs. 74%, P = 0.599) (Figure 3) . Compared with control subjects, intervention patients who were hospitalized during the trial (n = 41 and 45, respectively) were less than half as likely to be rehospitalized (incidence rate ratio, 0.46; P = 0.017). The number of rehospitalizations was 34 in the intervention group and 62 in the control group. The average length of hospital stay for all-cause hospitalization was 4.0 (IQR,1.0-9.0) days for the control group and 1.0 (IQR,1.0-6.7) days for the monitored group (P = 0.045). The total days hospitalized in the two groups were 669 days in the control group and 359 in the monitored group. The patients provided with cardiac monitoring (n = 37, 17% of the monitored patients) generated 19 (24%) of the recorded hospital admissions.
Quality of Life and Health Status
There were no significant between-group differences in the EQ-5D, CAT, or PHQ-9 scores at 9 months (Table 2) , nor did the MLHFQ scores differ in patients with CHF and/or IHD.
Cost Effectiveness
There was no statistically significant change in QALYs between intervention and control groups (0.485 vs. 0.491; P = 0.731; Table 2 ). There was a potentially significant reduction in the mean cost per patient in the intervention group compared with the control group (V3,547 vs. V4,831; P = 0.011; Table 2 ).
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Subgroup Analysis
There were no significant differences between intervention and control groups in the baseline characteristics of the subgroups (Table E4 ). There was no difference between treatments in TTFH and EQ-5D utility score at 9 months in any subgroup. However, monitored patients previously hospitalized for a COPD exacerbation showed a 53% reduction (P = 0.017) in their observed hospitalization rate compared with the control group (Figure 3 ). There was no difference in QALYs between intervention and control groups in any subgroup. The mean cost per patient in the intervention group was lower than in the control group for all the analyzed subgroups except for the subgroup with severe or very severe COPD. The largest differences were seen in patients with a previous hospitalization with COPD (V4,147 vs. V6,949; P = 0.008) and those with cardiac comorbidities (V4,237 vs. V6,520; P = 0.014).
Discussion
This is the first randomized trial to test whether daily telemonitoring with objective measurements of resting lung function and cardiac variables (where appropriate) can detect COPD exacerbations early and reduce the chance of hospitalization. Despite the acceptability of the monitoring system to patients, with a high adherence rate, its use did not affect overall TTFH, admission rate, or patient's quality of life assessed by EQ-5D. However, there was a potential for reduced healthcare costs, mostly due to a 54% decrease in repeat hospital admissions, a post hoc secondary outcome, without any increase in other healthcare costs. The cost difference varied between patients, being greatest in those who were hospitalized in the previous year. Although a few studies have suggested that combining symptoms and physiological variables, such as pulse and oxygen saturation, can identify COPD exacerbations (34), subsequent randomized trials have not shown any effect of monitoring on TTFH and/or patients' quality of life, similar to our findings (11-13, 15, 16) . However, although other trials recruited previously hospitalized patients, we studied patients with COPD reporting one or more exacerbations in the previous year (i.e., a broader group of patients with less severe disease). Although we saw no difference between groups in the TTFH (our primary study endpoint), there was a difference in the mean duration of hospital stay and the total days hospitalized after an emergency admission in favor of the monitored patients. Exacerbation duration is an important determinant of the risk for future exacerbation and disease progression (35) , and this may explain why patients who were hospitalized during the trial were significantly less likely to have a further hospitalization when they were monitored. When we Patients with only one exacerbation in the previous year 59 (37) 63 (41) Patients with more than one exacerbation in the previous year 99 (63) 91 (59) Patients with one exacerbation in the previous 3 mo 66 (42) 50 (32) Patients with more than one exacerbation in the previous 3 mo 22 (14) 25 (16) Patients hospitalized in the previous year 65 (41) 64 (42) Definition of abbreviations: BMI = body mass index; CAT = Chronic Obstructive Pulmonary Disease Assessment Tool; CHF = congestive heart failure; EQ-5D = EuroQol 5D; GOLD = Global Initiative for Chronic Obstructive Lung Disease (2007); IHD = ischemic heart disease; MLHF = Minnesota Living with Heart Failure questionnaire; PHQ-9 = Patient Health Questionnaire-9; VAS = visual analogue scale. Data presented as n (%) or median (interquartile range) unless otherwise noted.
restricted our analysis to patients hospitalized in the year before enrollment, a group at higher risk of subsequent hospitalization (36), there was a 53% reduction in hospitalization rate in monitored patients. This effect on rehospitalization may relate to the need for a run-in period to maximize the benefit of telemonitoring or to a reduction in exacerbation severity during the first or subsequent hospitalizations. This latter effect may result from earlier detection of exacerbations, as there is evidence that earlier treatment decreases the duration of exacerbations (37) .
We based respiratory alerts on daily measurements of lung mechanics by tidal oscillatory mechanics, thereby automating the system and reducing dependence on the patient's self-reported symptoms (38) . The CHROMED telemonitoring system detected changes that preceded half the hospitalizations early enough to permit intervention. Not all of these alerts identified events considered important by the clinical staff, although some alerts did precede subsequent hospitalization, even when no extra treatment was given. Our data support other observations on the diversity of time course and response to treatment of COPD exacerbations (39, 40) .
Patients with COPD were able to perform daily lung function measurements during tidal breathing over an extended period, with high adherence rate (88% recordings completed) and low dropout (73% completed the study). The attrition rate was similar between groups and there was little difference from comparable clinical trials performed on similar patients with similar duration (23% [41] , 50% [12] , 22% [11] ). As there was no difference between study arms, we can hypothesize that the attritions were mostly due to the multiple contacts for collecting questionnaires and the feeling of limitation in freedom to act induced by participating in a clinical trial rather than specific issues related to the monitoring procedures. The number of respiratory alerts per patient was roughly one every 2 months, a small . Incidence rate ratio of (A) hospitalizations and (B) systemic corticosteroid/antibiotic prescriptions in all patients and exploratory subgroups. Data presented are ratio and 95% confidence intervals. ALL = all patients; CHF = congestive heart failure; CI = confidence interval; COPD = chronic obstructive pulmonary disease; IHD = ischemic heart disease.
number compared with other similar telemonitoring trials in which alerts were based on symptoms and/or other variables (11, 12, 42) . Compared with those studies, the monitoring system based on continuous self-evaluation of lung function by FOT led to neither a major increase in time burden for healthcare personnel nor an increase in drug prescriptions when compared with standard practice, allowing it to be incorporated into a clinical service. Despite being used in a smaller group of patients, the cardiac monitor generated more alerts (1 alert/patient/mo instead of the 0.5 alert/patient/mo generated by FOT monitoring), similar to other studies (11) that resulted in more changes in therapy. However, the number of hospitalizations in this group of patients was similar to the other patients. At present, the economic benefit of telemonitoring in COPD remains unclear Definition of abbreviations: CAT = COPD Assessment Tool; CHF = congestive heart failure; CI = confidence interval; COPD = chronic obstructive pulmonary disease; EQ-5D = EuroQol 5D; IHD = ischemic heart disease; IRR = incidence rate ratio; MLHF = Minnesota Living with Heart Failure questionnaire; PHQ-9 = Patient Health Questionnaire-9; QALY = quality-adjusted life-year; VAS = visual analogue scale.
(43), reflecting the difficulty in isolating the effects of telemonitoring from educational interventions (44) . It is important to be cautious when interpreting data from a trial whose primary endpoints were not met, as is the case with CHROMED. Nonetheless, applying our prespecified health economic analysis suggested that there was a reduction in the healthcare costs in the intervention arm, with an average saving of V1,712 (27% lower) per patient per year, largely driven by a reduction in hospital costs. Although the additional costs for the hospital to manage the alerts were included in the analysis, the costs of the equipment and technical support were not included, as the CHROMED platform was still a prototype. Equipment and technical support costs tend to differ across countries and are often the result of a negotiation process between hospital and provider according to different factors, such as volumes. For telemonitoring to be truly cost effective, the annual cost of equipment and technical support must be less than the annualized difference in costs between intervention and control groups. Using previously published values as an estimate of the yearly costs for installation, training, and maintenance (V58) (17) and V53 for broadband contract (estimate from the trial), the system would be cost effective if the annual rental/purchase costs of the equipment were less than V1,600 per patient. Our exploratory subgroup analyses considered patients at greater risk of hospitalization, who might benefit more from telemonitoring. Previously hospitalized patients showed the largest cost savings exclusive of equipment costs (V3,736/patient/yr), suggesting that future studies should target this population. In patients with cardiac disease, there was a similar reduction in hospitalization, although this difference did not reach even notional significance.
Limitations of the Study
The size and objective nature of the monitoring system are particular strengths of our study. However, we were limited by the lower-than-expected number of hospitalizations and the variation in the pattern of health care between healthcare systems, which precluded our mandating specific interventions in response to an alert. There may have been differences in the threshold for hospitalization, and we did not have an independent study endpoint committee to review the causes of death. Inevitably, in a study of this kind, both the participants and study team were unblinded to the nature of the intervention. However, data about healthcare resource use was obtained and analyzed independently of the clinical study team.
To avoid bias from variation in costs across countries and improve its robustness, the economic evaluation was based on the costs of each intervention in a single country (United Kingdom) (45, 46) . The actual magnitude of the cost savings should therefore be adjusted when different healthcare systems are considered. Moreover, the costs of the equipment and technical support should be carefully taken into account when the prototype platform is marketed. As a relatively small number of patients (24%) used the cardiac monitoring system, we cannot assess the cost effectiveness of this tool.
Conclusions
We found that telemonitoring of older patients with COPD, using forced oscillation methodology together with cardiac monitoring in patients with significant cardiac comorbidities, was practical, well tolerated, and acceptable. Telemonitoring did not influence TTFH or our measure of general health status, the primary study outcomes. However, in an exploratory analysis there were fewer exacerbations in patients with recent hospitalizations and fewer readmissions in those who were hospitalized, changes that could translate into a health economic gain depending on the costs of any commercialized system. Whether cardiac monitoring in selected patients confers additional benefit is unclear and merits further study. Although ours was a negative clinical trial, it strongly suggests that using objectively defined criteria for clinical deterioration may be of value in patients with COPD at risk of hospitalization, and this group should be the focus of future investigations. n Author disclosures are available with the text of this article at www.atsjournals.org.
